These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39473179)

  • 1. Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression.
    Fiduccia I; Corrao F; Zizzo MG; Perriera R; Genovese F; Vitale E; Ricci D; Melfi R; Tutone M; Pace A; Lentini L; Pibiri I
    Mol Ther; 2024 Dec; 32(12):4514-4523. PubMed ID: 39473179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR.
    Karri S; Cornu D; Serot C; Biri L; Hatton A; Dréanot E; Rullaud C; Pranke I; Sermet-Gaudelus I; Hinzpeter A; Bidou L; Namy O
    J Cyst Fibros; 2024 Nov; 23(6):1185-1194. PubMed ID: 39098506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR
    Solomon GM; Linnemann RW; Rich R; Streby A; Buehler B; Hunter E; Vijaykumar K; Hunt WR; Brewington JJ; Rab A; Bai SP; Westbrook AL; McNicholas-Bevensee C; Hong J; Manfredi C; Barilla C; Suzuki S; Davis BR; Sorscher EJ
    Lancet Respir Med; 2024 Dec; 12(12):947-957. PubMed ID: 39208836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.
    Davies JC; Polineni D; Boyd AC; Donaldson S; Gill DR; Griesenbach U; Hyde SC; Jain R; McLachlan G; Mall MA; Alton EWFW
    Am J Respir Crit Care Med; 2024 Dec; 210(12):1398-1408. PubMed ID: 39236265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators.
    Yıldız CA; Selçuk Balcı M; Karabulut Ş; Başer ZM; Yüksel Kalyoncu M; Metin Çakar N; Akkitap Yiğit MM; Baysal EE; Özdemircioğlu F; Uzunoğlu B; Taştan G; Ergenekon P; Gökdemir Y; Erdem Eralp E; Karakoç F; Ata P; Karadağ B
    Pediatr Pulmonol; 2024 Dec; 59(12):3250-3259. PubMed ID: 39031495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Functional Impact of VX-770 on the Cystic Fibrosis Transmembrane Conductance Regulator Is Enduring and Increases the Constitutive Activity of This Channel in Primary Airway Epithelia Generated from Healthy Donors.
    Nick HJ; Christeson SE; Bratcher PE
    Biomolecules; 2024 Oct; 14(11):. PubMed ID: 39595555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.
    Amati F; Leonardi G; Contarini M; Morlacchi LC; Stainer A; Pizzamiglio G; Aliberti S; Blasi F; Gramegna A
    Ther Adv Respir Dis; 2024; 18():17534666241253945. PubMed ID: 39582115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics.
    Yıldız CA; Selçuk Balcı M; Karabulut Ş; Başer ZM; Kalyoncu M; Metin Çakar N; Akkitap Yiğit MM; Baysal EE; Özdemircioğlu F; Uzunoğlu B; Taştan G; Ergenekon P; Gökdemir Y; Erdem Eralp E; Karakoç F; Ata P; Karadağ B
    Pediatr Pulmonol; 2024 Dec; 59(12):3540-3549. PubMed ID: 39291770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel function.
    Hampton TH; Barnaby R; Roche C; Nymon A; Fukutani KF; MacKenzie TA; Charpentier LA; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2024 Dec; 327(6):L905-L916. PubMed ID: 39437760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).
    Ciobanu DZ; Liessi N; Tomati V; Capurro V; Bertozzi SM; Summa M; Bertorelli R; Loberto N; Dobi D; Aureli M; Nobbio L; Bandiera T; Pedemonte N; Bassi R; Armirotti A
    J Cyst Fibros; 2024 Nov; 23(6):1167-1172. PubMed ID: 38789319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elexacaftor/tezacaftor/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience.
    Fragoso E; Boaventura R; Almeida L; Amorim A; Gamboa F; Santos AS; Gonçalves F; Cruz CM; Carreiro A; Gonçalves AS; Teixeira V; Azevedo P
    Pulm Pharmacol Ther; 2024 Dec; 87():102328. PubMed ID: 39299648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function.
    Michicich M; Traylor Z; McCoy C; Valerio DM; Wilson A; Schneider M; Davis S; Barabas A; Mann RJ; LePage DF; Jiang W; Drumm ML; Kelley TJ; Conlon RA; Hodges CA
    J Cyst Fibros; 2024 Nov; ():. PubMed ID: 39532588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-pharmacophore based virtual screening of potent lead molecules against Cystic Fibrosis: An in silico study.
    Jeyaraman S; Sankar J; Wong LS; Muthusamy K
    Comput Biol Chem; 2024 Dec; 113():108249. PubMed ID: 39427605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of COVID-19 in cystic fibrosis patients: a review.
    Abolhasani FS; Moein M; Rezaie N; Sheikhimehrabadi P; Shafiei M; Afkhami H; Modaresi M
    Front Microbiol; 2024; 15():1356926. PubMed ID: 38694803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CFTR deficient iPSC-macrophages reveal impaired functional and transcriptomic response upon
    Rodriguez Gonzalez C; Basílio-Queirós D; Neehus AL; Merkert S; Tschritter D; Ünal S; Hegermann J; Mörgelin M; Bustamante J; Nietert MM; Martin U; Tümmler B; Munder A; Lachmann N
    Front Immunol; 2024; 15():1397886. PubMed ID: 39606224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
    Danahay H; Gosling M; Fox R; Lilley S; Charlton H; Hargrave JD; Schofield TB; Hay DA; Went N; McMahon P; Marlin F; Scott J; Vile J; Hewison S; Ellam S; Brown S; Sabater J; Kennet G; Lightowler S; Collingwood SP
    Eur J Med Chem; 2025 Jan; 282():117040. PubMed ID: 39561495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases.
    Bhat S; Bhattacharya A; Li H; Cui X; Lueck JD; Goldman YE; Cooperman BS
    bioRxiv; 2024 Dec; ():. PubMed ID: 39605609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Low Testosterone in Men With Cystic Fibrosis and Congenital Bilateral Absence of the Vas Deferens: A Cross-sectional Study Using a Large, Multi-institutional Database.
    Campbell K; Deebel N; Kohn T; Passarelli R; Velez D; Ramasamy R
    Urology; 2023 Dec; 182():143-148. PubMed ID: 37716455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.
    Massie RJ; Poplawski N; Wilcken B; Goldblatt J; Byrnes C; Robertson C
    Eur Respir J; 2001 Jun; 17(6):1195-200. PubMed ID: 11491164
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.